Lung Diseases in Children: From Rarer to Commonest

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Pulmonary and Sleep Medicine".

Deadline for manuscript submissions: closed (5 May 2023) | Viewed by 17592

Special Issue Editors


E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, Pediatric Respiratory Unit, University of Catania, 95124 Catania, Italy
Interests: clinical investigation; translational research; pediatric; pulmonology; allergology; cystic fibrosis
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, University of Catania, 95131 Catania, Italy
Interests: lung; malformations; genetics; children; prematurity; congenital pulmonary diseases; acquired pulmonary diseases

Special Issue Information

Dear Colleagues,

Pulmonary diseases are common acute and chronic diseases in the general population, including in children. These diseases can occur from very early childhood or later in life; then, they can remain stable or evolve into other forms of disease until adulthood. The prevalence and economic burden associated with this disease are increasing worldwide, despite therapeutic advances. Thus, the management of pulmonary diseases has become a vital concern in the medical field. In parallel, pediatricians have had to alter their approach to many pulmonary diseases, since this approach has to be constantly updated, both from a pathogenic and therapeutic perspective. Pediatric pulmonology is highly relevant, as many overlapping areas require a combined approach that leads to a complete understanding of the disease processes.

This Research Topic aims to update the knowledge on the pathogenesis, clinical presentation, diagnosis, and treatment of congenital and acquired pulmonary diseases, related, in particular, to the pediatric population. Papers focused on rare pulmonary diseases will be most welcome, and will receive special attention. Due to the low prevalence and severity of many of these diseases, whose symptoms often initially manifest in early infancy, combined efforts are required to improve the understanding of the pathophysiology and diagnostic management of these diseases, as well as to develop novel and more effective treatments.

Finally, in the era of the COVID-19 pandemic, any research on the diagnostic and therapeutic management of patients suffering from pulmonary diseases, who have been infected with SARS-CoV2, is especially welcome.

We invite authors to submit original articles, review articles, case reports, and clinical, epidemiologic, public health, and quality improvement research on the abovementioned research areas.

Dr. Salvatore Leonardi
Dr. Sara Manti
Dr. Giuseppe Fabio Parisi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonology
  • pulmonary diseases
  • congenital pulmonary diseases
  • acquired pulmonary diseases
  • diagnosis
  • treatment
  • childhood

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (8 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

9 pages, 1969 KiB  
Article
Airway Epithelial Cultures of Children with Esophageal Atresia as a Model to Study Respiratory Tract Disorders
by Henriette H. M. Dreyer, Eleonora Sofie van Tuyll van Serooskerken, Lisa W. Rodenburg, Arnold J. N. Bittermann, Hubertus G. M. Arets, Ellen M. B. P. Reuling, Johannes W. Verweij, Eric G. Haarman, David C. van der Zee, Stefaan H. A. J. Tytgat, Cornelis K. van der Ent, Jeffrey M. Beekman, Gimano D. Amatngalim and Maud Y. A. Lindeboom
Children 2023, 10(6), 1020; https://doi.org/10.3390/children10061020 - 5 Jun 2023
Viewed by 1564
Abstract
Esophageal atresia (EA) is a rare birth defect in which respiratory tract disorders are a major cause of morbidity. It remains unclear whether respiratory tract disorders are in part caused by alterations in airway epithelial cell functions such as the activity of motile [...] Read more.
Esophageal atresia (EA) is a rare birth defect in which respiratory tract disorders are a major cause of morbidity. It remains unclear whether respiratory tract disorders are in part caused by alterations in airway epithelial cell functions such as the activity of motile cilia. This can be studied using airway epithelial cell culture models of patients with EA. Therefore, the aim of this study was to evaluate the feasibility to culture and functionally characterize motile cilia function in the differentiated air–liquid interface cultured airway epithelial cells and 3D organoids derived from nasal brushings and bronchoalveolar lavage (BAL) fluid from children with EA. We demonstrate the feasibility of culturing differentiated airway epithelia and organoids of nasal brushings and BAL fluid of children with EA, which display normal motile cilia function. EA patient-derived airway epithelial cultures can be further used to examine whether alterations in epithelial functions contribute to respiratory disorders in EA. Full article
(This article belongs to the Special Issue Lung Diseases in Children: From Rarer to Commonest)
Show Figures

Figure 1

11 pages, 236 KiB  
Article
A Multicentre Italian Study on the Psychological Impact of an Inconclusive Cystic Fibrosis Diagnosis after Positive Neonatal Screening
by Antonella Tosco, Diletta Marino, Sara Polizzi, Valentina Tradati, Rita Padoan, Claudia Giust, Benedetta Fabrizzi, Giovanni Taccetti, Lucia Merli and Vito Terlizzi
Children 2023, 10(2), 177; https://doi.org/10.3390/children10020177 - 18 Jan 2023
Cited by 7 | Viewed by 2062
Abstract
Background: An inconclusive diagnosis of cystic fibrosis (CF) after positive newborn screening (NBS) may cause parental distress. We compared the psychological impact of CF transmembrane conductance regulator-related metabolic syndrome (CRMS)/CF screen-positive, inconclusive diagnosis (CFSPID), and clear CF diagnosis, on parents. Methods: The participants [...] Read more.
Background: An inconclusive diagnosis of cystic fibrosis (CF) after positive newborn screening (NBS) may cause parental distress. We compared the psychological impact of CF transmembrane conductance regulator-related metabolic syndrome (CRMS)/CF screen-positive, inconclusive diagnosis (CFSPID), and clear CF diagnosis, on parents. Methods: The participants were administered the Generalized Anxiety Disorder Scale, Patient Health Questionnaire-9, and the Italian version of the Impact of Event Scale-Revised as quantitative tools and semi-structured interviews as qualitative tools. Parental experience, child representation, relationships, future information, and perception of health status were investigated. Interviews were recorded and transcribed verbatim maintaining anonymity. Results: Thirty-two families were enrolled: sixteen with CF and CRMS/CFSPID, respectively. Anxiety and depression values were high in both groups, as were the measurement of traumatic impact subscales: avoidance, intrusiveness, and hyperarousal. The children’s health was evaluated by respective parents as being nearly healthy. Conclusions: Our results highlight negative psychological impacts, including emotional and affective representations, on parents of children with inconclusive CF diagnosis compared with those with clear diagnosis. Full article
(This article belongs to the Special Issue Lung Diseases in Children: From Rarer to Commonest)
10 pages, 5460 KiB  
Article
Clinical Presentation and Surgical Management of Five Pediatric Cases with Bronchogenic Cysts: Retrospective Case Series
by Ali Alsuheel Asseri, Ayed A. Shati, Amal Y. Moshebah, Omair M. Alshahrani, Rayan M. Saad, Abdulmohsin M. Alzuhari, Maraam M. Al Qout and Abdullah S. Al-Helal
Children 2022, 9(12), 1824; https://doi.org/10.3390/children9121824 - 25 Nov 2022
Cited by 2 | Viewed by 2611
Abstract
Background: Bronchogenic cysts (BCs) refer to congenital lesions that result from primitive or abnormal foregut budding, and can be pulmonary or mediastinal. Their occurrence can take place at any point on the tracheobronchial tree, but they are usually localized in the lung parenchyma [...] Read more.
Background: Bronchogenic cysts (BCs) refer to congenital lesions that result from primitive or abnormal foregut budding, and can be pulmonary or mediastinal. Their occurrence can take place at any point on the tracheobronchial tree, but they are usually localized in the lung parenchyma and mediastinum, and may be symptomatic or asymptomatic. Bronchogenic cyst symptoms can vary, depending on the size and location of the cyst. Methods: A retrospective review of the charts of five patients with a histopathological diagnosis of bronchogenic cysts was performed between 2014 and 2020. The patients reported in this study were diagnosed and managed at Abha Maternity and Children Hospital, Abha, southwest Saudi Arabia. In addition, demographic information, as well as diagnostic and therapeutic information, was provided for each patient, both at discharge and after discharge. All patients had confirmed congenital bronchogenic cysts with different clinical phenotypes and radiological findings. Results: All patients had histopathologically confirmed bronchogenic cysts with different clinical and radiological presentations. Two patients had mediastinal-located cysts; one had a laryngeal cyst; and the last two patients had infected intrapulmonary bronchogenic cysts. All patients underwent complete excision and did not experience recurrence or other postoperative complications during the follow-up period. The latter two patients required lobectomies of the right middle and upper lobes. Conclusions: Although bronchogenic cysts are considered a rare congenital pulmonary malformation, they should be considered in the differential diagnosis of pediatric patients with unusual airway and parenchymal lung manifestations, particularly, persistent stridor, feeding difficulty, and complicated pneumonia. Surgical excision of the cyst is the gold-standard therapy for symptomatic bronchogenic cysts and is highly recommended for asymptomatic ones. Long-term follow-up studies will be required to explore any long-term complications of BCs, particularly regarding the malignancy transformation. Full article
(This article belongs to the Special Issue Lung Diseases in Children: From Rarer to Commonest)
Show Figures

Figure 1

8 pages, 246 KiB  
Article
Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series
by Vito Terlizzi, Giuseppe Fabio Parisi, Beatrice Ferrari, Chiara Castellani, Sara Manti, Salvatore Leonardi and Giovanni Taccetti
Children 2022, 9(11), 1625; https://doi.org/10.3390/children9111625 - 26 Oct 2022
Cited by 6 | Viewed by 1461
Abstract
Background: Dornase alfa (DNase) is the only mucus-degrading agent that has proven efficacy in cystic fibrosis (CF). Few studies have evaluated the effects of DNase on the lung clearance index (LCI). We report the experience of two CF centers in which LCI monitoring [...] Read more.
Background: Dornase alfa (DNase) is the only mucus-degrading agent that has proven efficacy in cystic fibrosis (CF). Few studies have evaluated the effects of DNase on the lung clearance index (LCI). We report the experience of two CF centers in which LCI monitoring was used to evaluate the efficacy of DNase therapy. Methods: This is a prospective and observational study, evaluating the effects of DNase therapy on LCI values in three CF children followed at CF centers in Florence and Catania, Italy. In both centers, LCI was performed routinely, every 3–6 months, based on the clinical picture and severity of the lung disease. In this study, we evaluated the LCI before and after long-term DNase therapy. Results: DNase improved LCI values in the absence of respiratory exacerbations: in case n. 1 LCI decreased by 39% in 16 months (from 11.1 to 6.8); in case n. 2 by 20% in 12 months (from 9.3 to 7.4); in case n. 3 by 24% in 16 months (from 9.3 to 7.0). Conclusions: This case series confirms the efficacy of DNase therapy in CF children, as demonstrated by the LCI reduction in treated patients. Furthermore, our results suggest that LCI is a sensitive marker of disease and can be used for the evaluation of response to treatment. Full article
(This article belongs to the Special Issue Lung Diseases in Children: From Rarer to Commonest)

Review

Jump to: Research, Other

9 pages, 569 KiB  
Review
Interstitial Lung Disease in Children: “Specific Conditions of Undefined Etiology” Becoming Clearer
by Santiago Presti, Giuseppe Fabio Parisi, Maria Papale, Eloisa Gitto, Sara Manti and Salvatore Leonardi
Children 2022, 9(11), 1744; https://doi.org/10.3390/children9111744 - 14 Nov 2022
Cited by 3 | Viewed by 1970
Abstract
Background: Children’s interstitial lung disease (chILD) is a rare group of pediatric lung diseases affecting the lung interstitium diffusely. In this work, we focused our attention on a specific infant group of chILD, also known as “specific conditions of undefined aetiology”, including pulmonary [...] Read more.
Background: Children’s interstitial lung disease (chILD) is a rare group of pediatric lung diseases affecting the lung interstitium diffusely. In this work, we focused our attention on a specific infant group of chILD, also known as “specific conditions of undefined aetiology”, including pulmonary interstitial glycogenosis (PIG) and neuroendocrine cell hyperplasia of infancy (NEHI). Methods: PubMed was searched to conduct this narrative review. We searched for articles in English using the following keywords: (1) neuroendocrine cell hyperplasia of infancy; (2) NEHI; (3) pulmonary interstitial glycogenosis; (4) PIG; (5) chILD. Results: An increasing interest and insight into these two conditions have been reported. The updated literature suggests that it is possible to look at these disorders as a continuum of diseases, rather than two different entities, since they share a pulmonary dysmaturity. Conclusions: NEHI and PIG are featured by dysmaturity of airway development and consequent respiratory distress. Understanding the underlying pathogenic mechanisms would lead to identifying new targeted therapies to ameliorate the mortality and morbidity of these rare conditions. Full article
(This article belongs to the Special Issue Lung Diseases in Children: From Rarer to Commonest)
Show Figures

Figure 1

Other

Jump to: Research, Review

7 pages, 1350 KiB  
Case Report
A Niemann–Pick Disease Type C2 with Severe Pulmonary Involvement and Limited Therapeutic Options: A Case Report
by Abdullah Al-Shamrani, Khalid Al-Shamrani, Ahmed Bin Mahfoudh, Ahmed Sarar Mohamed and Sarar Mohamed
Children 2022, 9(12), 1811; https://doi.org/10.3390/children9121811 - 24 Nov 2022
Cited by 2 | Viewed by 1924
Abstract
Niemann–Pick disease type C (NPC) is an autosomal recessive lipid storage disorder. There are two types, NPC1, which is the predominant form (95%), and the rare NPC2, which represents less than 5% of the reported cases. Niemann–Pick disease type C2 usually presents with [...] Read more.
Niemann–Pick disease type C (NPC) is an autosomal recessive lipid storage disorder. There are two types, NPC1, which is the predominant form (95%), and the rare NPC2, which represents less than 5% of the reported cases. Niemann–Pick disease type C2 usually presents with respiratory symptoms, cholestasis, neurological impairment, and hepatosplenomegaly. Case report: Here, we report a 3-year-old boy who presented to our hospital with exacerbation of chronic lung disease requiring invasive ventilatory support. He was previously diagnosed with interstitial lung disease. His parents used to instill olive oil in his nose (a few drops in each nostril daily for several months) to treat frequent nasal bleeding. A detailed history revealed prolonged neonatal jaundice for four months, with hepatosplenomegaly. In his second year, generalized hypotonia and delayed psychomotor development were observed. Upon presentation to our institute, chest CT showed evidence of intraparenchymal fat; therefore, lipoid pneumonia and lipid storage disease were suspected. The bronchoalveolar lavage results suggested pulmonary alveolar proteinosis (PAP). Whole-exome sequencing (WES) revealed a class one homozygous pathogenic variant in the NPC2 gene. Our patient faced a range of difficulties, including prolonged mechanical ventilation and diagnostic and therapeutic challenges. Conclusion: Niemann–Pick disease type C2 is a progressive and lethal condition that requires a high index of suspicion to pinpoint the diagnosis. Gene study remains the method of choice to confirm the diagnosis. There are limited choices of therapeutic interventions; therefore, genetic counseling and the prevention of recurrence should be the ultimate goal for affected families. Full article
(This article belongs to the Special Issue Lung Diseases in Children: From Rarer to Commonest)
Show Figures

Figure 1

6 pages, 463 KiB  
Case Report
Spontaneous Pneumomediastinum in a 16-Year-Old Patient with SARS-CoV-2 Infection: A North-East Romanian Case
by Florin Filip, Monica Terteliu Baitan, Olga Adriana Caliman Sturdza, Roxana Gheorghita Puscaselu and Roxana Filip
Children 2022, 9(11), 1641; https://doi.org/10.3390/children9111641 - 27 Oct 2022
Cited by 2 | Viewed by 1547
Abstract
Spontaneous pneumomediastinum (SPM) associated with SARS-CoV-2 infection is a rare condition but can represent a medical emergency. It is probably related to alveolar damage secondary to SARS-CoV-2 infection, which allows air to escape in the surrounding lung tissue. Cough and airways’ barotrauma are [...] Read more.
Spontaneous pneumomediastinum (SPM) associated with SARS-CoV-2 infection is a rare condition but can represent a medical emergency. It is probably related to alveolar damage secondary to SARS-CoV-2 infection, which allows air to escape in the surrounding lung tissue. Cough and airways’ barotrauma are also mentioned as contributing mechanisms. Treatment is generally conservative, but surgery may be required in severe cases. This paper presents the case of a 16-year-old girl with COVID-19-associated SPM who was treated conservatively in our department. The clinical course was favorable with resolution of respiratory symptoms and radiological (chest CT scan) image of pneumomediastinum. The patient was discharged 7 days after the confirmation of the initial SP diagnosis with appropriate treatment and recommendations for isolation. The sudden occurrence of chest pain and dyspnea should raise the suspicion of SPM in COVID-19 patients. Close surveillance and proper radiological monitoring are required in such cases. Treatment should be strictly individualized based on clinical course and radiological appearance. Full article
(This article belongs to the Special Issue Lung Diseases in Children: From Rarer to Commonest)
Show Figures

Graphical abstract

16 pages, 691 KiB  
Systematic Review
Antibiotherapy in Children with Cystic Fibrosis—An Extensive Review
by Ioana Mihaiela Ciuca, Mihaela Dediu, Diana Popin, Liviu Laurentiu Pop, Liviu Athos Tamas, Ciprian Nicolae Pilut, Bogdan Almajan Guta and Zoran Laurentiu Popa
Children 2022, 9(8), 1258; https://doi.org/10.3390/children9081258 - 20 Aug 2022
Cited by 11 | Viewed by 3257
Abstract
In cystic fibrosis (CF), the respiratory disease is the main factor that influences the outcome and the prognosis of patients, bacterial infections being responsible for severe exacerbations. The etiology is often multi-microbial and with resistant strains. The aim of this paper is to [...] Read more.
In cystic fibrosis (CF), the respiratory disease is the main factor that influences the outcome and the prognosis of patients, bacterial infections being responsible for severe exacerbations. The etiology is often multi-microbial and with resistant strains. The aim of this paper is to present current existing antibiotherapy solutions for CF-associated infections in order to offer a reliable support for individual, targeted, and specific treatment. The inclusion criteria were studies about antibiotherapy in CF pediatric patients. Studies involving adult patients or those with only in vitro results were excluded. The information sources were all articles published until December 2021, in PubMed and ScienceDirect. A total of 74 studies were included, with a total number of 26,979 patients aged between 0–18 years. We approached each pathogen individual, with their specific treatment, comparing treatment solutions proposed by different studies. Preservation of lung function is the main goal of therapy in CF, because once parenchyma is lost, it cannot be recovered. Early personalized intervention and prevention of infection with reputable germs is of paramount importance, even if is an asymmetrical challenge. This research received no external funding. Full article
(This article belongs to the Special Issue Lung Diseases in Children: From Rarer to Commonest)
Show Figures

Figure 1

Back to TopTop